Click Therapeutics Announces Participation in Upcoming Investor Conferences
NEW YORK – September 14, 2022 – Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced that Randall Stanicky, Chief Financial Officer, will present at the following virtual investor conferences in September.
Event: LifeSci Partners HealthTech Symposium
Date: Tuesday, September 20, 2022
Time: 8:00 a.m. ET
Event: UBS Biotechnology Private Company Virtual Symposium
Date: Wednesday, September 21, 2022
Time: 8:30 a.m. ET
For additional information, please reach out to the respective conference organizers.
About Click Therapeutics
Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for patients with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program has entered a pivotal, fully remote, randomized, controlled trial on the Verily platform for the treatment of Major Depressive Disorder (MDD) in up to 360 adults. Click is progressing a broad pipeline of Digital Therapeutics™ across a variety of high-burden therapeutic areas, including MDD, Schizophrenia, Migraine, Chronic Pain, Atopic Dermatitis, Acute Coronary Syndrome (ACS), Obesity and more. For more information on Click, visit ClickTherapeutics.com
VP, Investor Relations & Strategic Finance